Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

SEEL

Seelos Therapeutics Inc

Last Close
May 17 • 01:17PM ET
1.91
Dollar change
-0.43
Percentage change
-18.38 		%
Held by: PSIL VTI VXF ITOT Scroll to Statements
Index- P/E- EPS (ttm)-42.75 Insider Own8.70% Shs Outstand17.38M Perf Week-10.91%
Market Cap33.20M Forward P/E- EPS next Y- Insider Trans11.73% Shs Float15.87M Perf Month-29.36%
Income-27.11M PEG- EPS next Q- Inst Own13.10% Short Float0.82% Perf Quarter-71.20%
Sales1.97M P/S16.85 EPS this Y- Inst Trans-46.15% Short Ratio2.05 Perf Half Y-93.40%
Book/sh-17.36 P/B- EPS next Y- ROA-198.99% Short Interest0.13M Perf Year-99.18%
Cash/sh0.03 P/C63.84 EPS next 5Y- ROE-584.20% 52W Range1.92 - 398.40 Perf YTD-82.82%
Dividend Est.- P/FCF- EPS past 5Y62.30% ROI- 52W High-99.52% Beta2.01
Dividend TTM- Quick Ratio0.10 Sales past 5Y-20.00% Gross Margin97.06% 52W Low-0.52% ATR (14)0.41
Dividend Ex-Date- Current Ratio0.10 EPS Y/Y TTM74.71% Oper. Margin-1905.88% RSI (14)32.12 Volatility16.21% 12.87%
Employees16 Debt/Eq- Sales Y/Y TTM144.31% Profit Margin-1373.61% Recom1.00 Target Price32.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q94.28% Payout- Rel Volume4.97 Prev Close2.34
Sales Surprise42.13% EPS Surprise-1867.60% Sales Q/Q-28.34% Earnings- Avg Volume63.36K Price1.91
SMA20-19.66% SMA50-53.79% SMA200-96.93% Trades Volume189,819 Change-18.38%
Date Action Analyst Rating Change Price Target Change
Sep-27-21Upgrade ROTH Capital Neutral → Buy $2.50 → $8
Jul-01-21Initiated Guggenheim Buy $8
Jun-01-21Initiated Cantor Fitzgerald Overweight $10
May-17-21Downgrade ROTH Capital Buy → Neutral
Mar-30-21Initiated B. Riley Securities Buy $15
Nov-14-19Initiated The Benchmark Company Speculative Buy $4
May-14-19Initiated ROTH Capital Buy
May-16-24 11:45PM
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
(PR Newswire)
May-14-24 01:53PM
SEEL Stock Earnings: Seelos Therapeutics Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace) -11.89%
12:48PM
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance
(MT Newswires)
11:45AM
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
(PR Newswire)
08:12AM
Seelos: Q1 Earnings Snapshot
(Associated Press Finance)
08:00AM Loading…
Apr-29-24 08:00AM
Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
(PR Newswire)
Mar-22-24 01:53PM
SEEL Stock Earnings: Seelos Therapeutics Beats EPS for Q4 2023
(InvestorPlace)
Mar-19-24 08:43AM
UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study
(Reuters) -29.18%
08:23AM
Seelos says ALS treatment fails in mid-stage study
(Reuters)
08:15AM
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
(PR Newswire)
Jan-26-24 08:30AM
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
(PR Newswire)
Jan-24-24 09:00AM
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
(PR Newswire) -10.74%
Jan-22-24 08:00AM
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
(PR Newswire)
Jan-09-24 01:56PM
Therapys New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
(InvestorPlace) +25.17%
Jan-02-24 08:00AM
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote 'FOR' All Proxy Proposals at the Special Meeting to be held on January 10, 2024
(PR Newswire)
08:47AM Loading…
Dec-29-23 08:47AM
11 Best Psychedelic Stocks to Buy in 2024
(Insider Monkey)
Dec-22-23 08:00AM
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
(PR Newswire) +5.41%
Dec-20-23 02:15PM
11 Most Promising Psychedelic Stocks According to Hedge Funds
(Insider Monkey) -8.39%
Dec-02-23 05:05AM
Insider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)
(GuruFocus.com)
Dec-01-23 04:00PM
Seelos Therapeutics Announces Closing of Public Offering
(PR Newswire) +9.52%
Nov-29-23 08:53AM
Why Is Seelos Therapeutics (SEEL) Stock Down 42% Today?
(InvestorPlace) -47.48%
Nov-28-23 09:26PM
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
(PR Newswire) -25.37%
04:06PM
Seelos Therapeutics Announces Proposed Public Offering
(PR Newswire)
Nov-27-23 08:00AM
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
(PR Newswire) -18.79%
Nov-24-23 10:53AM
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
(PR Newswire) -22.95%
Nov-15-23 05:06AM
Seelos: Q3 Earnings Snapshot
(Associated Press Finance)
Oct-27-23 08:11AM
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
(PR Newswire)
Oct-17-23 08:00AM
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
(PR Newswire) +8.33%
Sep-27-23 08:00AM
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
(PR Newswire) +13.54%
Sep-25-23 07:00AM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
(Market Exclusive)
10:06AM Loading…
Sep-21-23 10:06AM
Enphase Energy upgraded, Brighthouse downgraded: Wall Street's top analyst calls
(The Fly) -37.73%
09:00AM
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
(PR Newswire)
Sep-20-23 07:00AM
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
(PR Newswire) -69.49%
Sep-06-23 08:17PM
7 Biotech Stocks to Sell in September Before They Crash & Burn
(InvestorPlace) -5.61%
Aug-14-23 08:00AM
Seelos Therapeutics Provides Second Quarter 2023 Clinical Update
(PR Newswire) -7.64%
Aug-13-23 09:58AM
Seelos Therapeutics' (NASDAQ:SEEL) investors will be pleased with their decent 52% return over the last year
(Simply Wall St.)
Jun-22-23 08:00AM
Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)
(PR Newswire) +6.60%
May-30-23 07:00AM
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
(Market Exclusive) -6.43%
May-22-23 08:00AM
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
(PR Newswire)
May-15-23 08:33AM
Seelos: Q1 Earnings Snapshot
(AP Finance) +6.92%
08:00AM
Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
(PR Newswire)
May-05-23 08:00AM
Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
(PR Newswire) +5.45%
Apr-04-23 08:00AM
Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
(PR Newswire)
Mar-30-23 10:21AM
Seelos Therapeutics Pauses Spinocerebellar Ataxia Study Citing Financial Considerations
(Benzinga)
Mar-29-23 04:05PM
Seelos Therapeutics Announces Business Update on its Key Programs
(PR Newswire)
Mar-12-23 12:22PM
10 Best Psychedelic Stocks to Buy According to Hedge Funds
(Insider Monkey)
Mar-10-23 09:00AM
Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
(PR Newswire) +11.86%
Feb-27-23 09:13AM
10 Most Promising Psychedelic Stocks According To Analysts
(Insider Monkey) +7.24%
Feb-15-23 09:21AM
Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference
(PR Newswire) +5.37%
Feb-13-23 08:00AM
Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
(PR Newswire)
Feb-10-23 08:00AM
Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
(PR Newswire)
Feb-06-23 08:00AM
Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
(PR Newswire)
Dec-22-22 08:00AM
Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event
(PR Newswire)
Dec-15-22 11:11AM
Parkinson's Study Using CRISPR Technology Shows Promise, Seelos Therapeutics Says
(Benzinga) -15.50%
08:00AM
Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
(PR Newswire)
Dec-08-22 08:00AM
Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
(PR Newswire)
Nov-23-22 08:00AM
Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022
(PR Newswire) +5.66%
Nov-07-22 12:56PM
Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day
(PR Newswire)
Nov-01-22 08:36AM
10 Penny Stocks To Buy That Are Too Cheap To Ignore
(Insider Monkey)
Oct-28-22 02:49PM
7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.
(InvestorPlace)
Oct-27-22 08:00AM
Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event
(PR Newswire)
Oct-25-22 08:00AM
Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia
(PR Newswire)
Sep-30-22 10:00AM
Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)
(PR Newswire)
Sep-13-22 08:00AM
Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder
(PR Newswire) +7.63%
Sep-09-22 09:00AM
Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference
(PR Newswire)
Aug-30-22 08:00AM
Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences
(PR Newswire) -7.76%
Aug-24-22 08:00AM
Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004
(PR Newswire) +17.87%
Jul-18-22 08:00AM
Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform
(PR Newswire)
Jun-09-22 08:00AM
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies
(PR Newswire)
Jun-06-22 12:47PM
A number of insiders bought Seelos Therapeutics, Inc. (NASDAQ:SEEL) stock last year, which is great news for shareholders
(Simply Wall St.)
May-18-22 08:00AM
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
(PR Newswire) -5.49%
May-12-22 08:00AM
Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
(PR Newswire)
Apr-22-22 11:00AM
Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference
(PR Newswire)
Apr-11-22 08:00AM
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Commercial Based Milestones and the Change of Control Fee
(PR Newswire)
Mar-08-22 08:00AM
Seelos Therapeutics Receives an Acknowledgement Letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a Pilot Study of SLS-005 in Alzheimer's Disease
(PR Newswire)
Mar-07-22 08:00AM
Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update
(PR Newswire)
Feb-28-22 08:00AM
Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
(PR Newswire)
Dec-21-21 04:05PM
Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(PR Newswire)
Dec-16-21 08:00AM
Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event
(PR Newswire)
Dec-06-21 08:01AM
Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007
(PR Newswire)
Nov-29-21 09:00AM
iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products
(PR Newswire) -5.95%
Nov-24-21 11:18AM
iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products
(PR Newswire)
08:16AM
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
(PR Newswire)
07:16AM
Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note
(PR Newswire)
Nov-23-21 07:03AM
10 Stock Picks of Nathaniel Augusts Mangrove Partners
(Insider Monkey) +8.33%
Nov-10-21 08:00AM
Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium
(PR Newswire)
Nov-09-21 11:18AM
Could The Seelos Therapeutics, Inc. (NASDAQ:SEEL) Ownership Structure Tell Us Something Useful?
(Simply Wall St.)
Nov-08-21 09:19AM
Seelos Therapeutics To Test Trehalose In Patients With Rare Movement Control Disorder
(Benzinga)
08:00AM
Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia
(PR Newswire)
Nov-02-21 08:00AM
Seelos Therapeutics to Participate in Two Investor Conferences
(PR Newswire)
Oct-25-21 02:00PM
Seelos Therapeutics Presents a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
(PR Newswire)
Oct-01-21 08:00AM
Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research
(PR Newswire)
Sep-27-21 12:59PM
Why Seelos Therapeutics Stock Is Trading Higher Today
(Benzinga) +14.35%
Sep-22-21 10:02AM
Is the Options Market Predicting a Spike in Seelos (SEEL) Stock?
(Zacks)
Sep-21-21 03:25PM
Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial
(Benzinga) +13.68%
Sep-09-21 08:00AM
Seelos Therapeutics to Participate in Two Investor Conferences in September
(PR Newswire)
Sep-02-21 08:00AM
Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors
(PR Newswire)
Sep-01-21 08:00AM
Seelos Therapeutics Announces Senior Management Appointments
(PR Newswire)
Aug-09-21 10:47AM
Companies Like Seelos Therapeutics (NASDAQ:SEEL) Are In A Position To Invest In Growth
(Simply Wall St.)
08:00AM
Seelos Therapeutics Announces Mid-Year 2021 Business and Clinical Update
(PR Newswire)
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mehra RajSee RemarksDec 01 '23Buy1.3275,75799,999185,142Dec 01 04:16 PM
Golembiewski Michael JosephChief Financial OfficerNov 30 '23Buy1.2183,000100,22286,450Dec 01 04:16 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.